Prosecution Insights
Last updated: October 04, 2026

Arbutus Biopharma Corporation

Technology area: Biotechnology & Pharmaceuticals

1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days

Analysis

Arbutus Biopharma Corporation has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is assigned to 1 distinct examiner, TATGE, LEXUS MARC, who is the busiest examiner for the portfolio with 1 pending case. Prosecution is limited to 1 distinct art unit. This indicates a very focused and centralized approach to the company's current active patent application, with all work handled by a single examiner.

With only one active matter and one assigned examiner, the company has a very streamlined presence at the patent office. This singular focus on the assigned art unit means that the company's current legal efforts are not diluted across multiple administrative channels. TATGE, LEXUS MARC holds total influence over the portfolio's current trajectory. Practitioners should prioritize a clear and direct communication line with this examiner to resolve any issues. Understanding the specific examination culture of this single art unit is essential for predicting the timeline and eventual outcome of the 1 pending office action.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

1
Total Pending OAs
1
Non-Final OAs
0
Final Rejections
0
Advisory / Quayle

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

0
Hard (0%)
1
Medium (100%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
Double-patenting + other1 (100%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

1
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

10 h
Manual time on pending OAs
2 h
Time saved (low, 20%)
4 h
Time saved (mid, 35%)
0.1 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
TATGE, LEXUS MARC 1 50.0% +100.0%

Interview Candidates (1)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18035695 TARGETED CONJUGATES COMPRISING MODIFIED SIRNA TATGE, LEXUS MARC —

Top Art Units

Art UnitApps
1637 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18035695 TARGETED CONJUGATES COMPRISING MODIFIED SIRNA TATGE, LEXUS MARC 1637 §102§103§112DP Non-Final OA — Pending May 05, 2023

Managing Arbutus Biopharma Corporation's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month